Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer’s Disease Pathology Between Three Independent Assay Platforms | Zendy

James D. Doecke | Zendy; Alan Rembach | Zendy; Victor L. Villemagne | Zendy; Shiji Varghese | Zendy; Stephanie R. RaineySmith | Zendy; Shan Sarros | Zendy; Lisbeth Evered | Zendy; Christopher Fowler | Zendy; Kelly K. Pertile | Zendy; Rebecca Rumble | Zendy; Brett Trounson | Zendy; Kevin Taddei | Zendy; Simon M. Laws | Zendy; S. Lance Macaulay | Zendy; Ashley I. Bush | Zendy; Kathryn A. Ellis | Zendy; Ralph N. Martins | Zendy; David Ames | Zendy; Brendan Silbert | Zendy; Hugo Vanderstichele | Zendy; Colin L. Masters | Zendy; David Darby | Zendy; QiaoXin Li | Zendy; Steven Collins | Zendy

Open Access

Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer’s Disease Pathology Between Three Independent Assay Platforms

Author(s) -

James D. Doecke,

Alan Rembach,

Victor L. Villemagne,

Shiji Varghese,

Stephanie R. RaineySmith,

Shan Sarros,

Lisbeth Evered,

Christopher Fowler,

Kelly K. Pertile,

Rebecca Rumble,

Brett Trounson,

Kevin Taddei,

Simon M. Laws,

S. Lance Macaulay,

Ashley I. Bush,

Kathryn A. Ellis,

Ralph N. Martins,

David Ames,

Brendan Silbert,

Hugo Vanderstichele,

Colin L. Masters,

David Darby,

QiaoXin Li,

Steven Collins

Publication year - 2017

Publication title -

journal of alzheimer s disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.677

H-Index - 139

eISSN - 1875-8908

pISSN - 1387-2877

DOI - 10.3233/jad-170128

Subject(s) - concordance , biomarker , cerebrospinal fluid , medicine , positron emission tomography , amyloid (mycology) , pathology , oncology , disease , dementia , alzheimer's disease neuroimaging initiative , nuclear medicine , biology , biochemistry

To enhance the accuracy of clinical diagnosis for Alzheimer's disease (AD), pre-mortem biomarkers have become increasingly important for diagnosis and for participant recruitment in disease-specific treatment trials. Cerebrospinal fluid (CSF) biomarkers provide a low-cost alternative to positron emission tomography (PET) imaging for in vivo quantification of different AD pathological hallmarks in the brains of affected subjects; however, consensus around the best platform, most informative biomarker and correlations across different methodologies are controversial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research